Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept timing with pars plana vitrectomy for proliferative diabetic retinopathy
ChiCTR2200061563Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jun 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of conbercept in proliferative diabetic retinopathy (PDR), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Occurrence of vitreous hemorrhage 7 days to 30 days after surgery. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ChiCTR2200061563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061563.